| P50 | author | Bjoern Schneider | Q89496385 |
| P2093 | author name string | Anselm Jünemann | |
| | Andreas Erbersdobler | |
| | Andrey Zhivov | |
| | Rudolf F Guthoff | |
| | Annette Zimpfer | |
| | Maja Huehns | |
| | Heike Zettl | |
| | Katrin Riedel | |
| P2860 | cites work | Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP | Q24298571 |
| | Mutations in GNA11 in uveal melanoma | Q24625723 |
| | Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi | Q24646052 |
| | Oncogenic mutations in GNAQ occur early in uveal melanoma | Q24658558 |
| | Recent developments in prognostic and predictive testing in uveal melanoma | Q26824096 |
| | The T1799A BRAF mutation is present in iris melanoma | Q28254902 |
| | Distinct sets of genetic alterations in melanoma | Q29614965 |
| | American joint committee on cancer staging of uveal melanoma | Q30448877 |
| | Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma | Q30649682 |
| | The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. | Q33799070 |
| | Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. | Q33819083 |
| | Does ocular treatment of uveal melanoma influence survival? | Q34059687 |
| | The genetics of uveal melanoma: an emerging framework for targeted therapy | Q34249080 |
| | High throughput mass spectrometry-based mutation profiling of primary uveal melanoma | Q34414476 |
| | Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. | Q36615986 |
| | Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma | Q36850230 |
| | Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11 | Q37040664 |
| | Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. | Q37330725 |
| | Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. | Q37340405 |
| | A study of PCR inhibition mechanisms using real time PCR. | Q38347942 |
| | Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives | Q38798084 |
| | Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma | Q41881966 |
| | YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations | Q41957475 |
| | Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea | Q43998617 |
| | Lack of BRAF mutations in uveal melanoma | Q44605105 |
| | The RAS-BRAF kinase pathway is not involved in uveal melanoma | Q47390207 |
| | Lack of BRAF mutation in primary uveal melanoma. | Q47807462 |
| | Genetic and clinico-pathologic analysis of metastatic uveal melanoma | Q47932446 |
| | Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas | Q60527002 |
| | Independent regulation of hair and skin color by two G protein-coupled pathways | Q62661037 |
| | Absence of BRAF and NRAS mutations in uveal melanoma | Q79107430 |
| | Uveal melanoma: current insights into clinical relevance of genetic testing | Q87133830 |
| P433 | issue | 4 | |
| P304 | page(s) | 1319-1325 | |
| P577 | publication date | 2017-12-05 | |
| P1433 | published in | Pathology and Oncology Research | Q26842743 |
| P1476 | title | Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas | |
| P478 | volume | 25 | |